AstraZeneca pays $2.5bn, plus earn-outs, for majority stake in Acerta Pharma
AstraZeneca PLC is further strengthening its blood cancer assets by acquiring a 55% stake in three-year-old private biopharma Acerta Pharma BV. Total consideration for the initial stake is $4bn, with $2.5bn payable up front and the remainder within the next three years.
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.